Aptose Biosciences Stock Price, News & Analysis (NASDAQ:APTO) $2.52 +0.29 (+13.00%) (As of 02:14 PM ET) Add Compare Share Share Today's Range$2.30▼$2.6050-Day Range$2.14▼$3.3252-Week Range$2.14▼$11.55Volume35,836 shsAverage Volume30,117 shsMarket Capitalization$19.00 millionP/E RatioN/ADividend YieldN/APrice Target$37.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Aptose Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,394.7% Upside$37.67 Price TargetShort InterestHealthy0.96% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 3 Articles This WeekInsider TradingAcquiring Shares$53,380 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($7.83) to ($5.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.41 out of 5 starsMedical Sector344th out of 949 stocksBiological Products, Except Diagnostic Industry53rd out of 161 stocks 3.5 Analyst's Opinion Consensus RatingAptose Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $37.67, Aptose Biosciences has a forecasted upside of 1,394.7% from its current price of $2.52.Amount of Analyst CoverageAptose Biosciences has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.96% of the float of Aptose Biosciences has been sold short.Short Interest Ratio / Days to CoverAptose Biosciences has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aptose Biosciences has recently decreased by 27.21%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAptose Biosciences does not currently pay a dividend.Dividend GrowthAptose Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for APTO. Previous Next 3.3 News and Social Media Coverage News SentimentAptose Biosciences has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Aptose Biosciences this week, compared to 1 article on an average week.Search Interest2 people have searched for APTO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Aptose Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aptose Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $53,380.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 9.53% of the stock of Aptose Biosciences is held by insiders.Percentage Held by InstitutionsOnly 1.07% of the stock of Aptose Biosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aptose Biosciences are expected to grow in the coming year, from ($7.83) to ($5.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aptose Biosciences is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aptose Biosciences is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAptose Biosciences has a P/B Ratio of 2.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aptose Biosciences Stock (NASDAQ:APTO)Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Read More APTO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APTO Stock News HeadlinesNovember 28, 2023 | americanbankingnews.comAptose Biosciences (NASDAQ:APTO) Stock Passes Below 50 Day Moving Average of $2.72November 19, 2023 | americanbankingnews.comAptose Biosciences Inc. (NASDAQ:APTO) Given Consensus Rating of "Buy" by AnalystsNovember 29, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!November 12, 2023 | seekingalpha.comAptose Biosciences Inc. (APTO) Q3 2023 Earnings Call TranscriptNovember 11, 2023 | benzinga.comAptose Biosciences Stock (NASDAQ:APTO) Earnings Dates and Earning CallsNovember 10, 2023 | benzinga.comAptose Biosciences: Q3 Earnings InsightsNovember 10, 2023 | markets.businessinsider.comPromising Financial Performance and Clinical Developments Bolster Aptose Biosciences’ Buy Rating: An Analysis by Joseph PantginisNovember 9, 2023 | msn.comAptose Biosciences GAAP EPS of -$1.76 beats by $0.22November 29, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!November 1, 2023 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Aptose Biosciences (APTO)November 1, 2023 | markets.businessinsider.comPromising Trial Data and Expansion Plans Boost Confidence in Aptose Biosciences: An Analysis of John Newman’s Buy RatingOctober 30, 2023 | finance.yahoo.comAptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug TuspetinibOctober 16, 2023 | finance.yahoo.comAptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International ConferenceOctober 12, 2023 | theglobeandmail.comAptose Biosciences: Bottom 25 Performing Stocks Year-to-Date on TSX (APS)September 8, 2023 | finance.yahoo.comCompanies Like Aptose Biosciences (TSE:APS) Could Be Quite RiskySeptember 7, 2023 | finance.yahoo.comHANMI FILES EARLY WARNING REPORT IN RESPECT OF APTOSE BIOSCIENCES INC.September 7, 2023 | markets.businessinsider.comExpert Ratings for Aptose BiosciencesAugust 24, 2023 | finance.yahoo.comAptose to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 23, 2023 | theglobeandmail.comClosing Bell: Aptose Biosciences Inc down on Tuesday (APS)August 18, 2023 | fool.comAptose Biosciences (NASDAQ: APTO)August 11, 2023 | markets.businessinsider.comRBC Capital Maintains Outperform Rating for Aptose Biosciences: Here's What You Need To KnowAugust 11, 2023 | msn.comAptose Biosciences GAAP EPS of -$2.27 misses by $0.34August 2, 2023 | msn.comAptose Biosciences (APTO) Price Target Increased by 1614.75% to 62.90July 28, 2023 | finance.yahoo.comAptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023June 27, 2023 | finance.yahoo.comAPTO - Aptose Biosciences Inc.June 26, 2023 | finance.yahoo.comAptose Biosciences Meets Nasdaq Minimum Bid Price ComplianceJune 12, 2023 | marketwatch.comAptose Shares Up 11% After Study Presentation, Analysts' Target BoostsSee More Headlines Receive APTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/23/2023Today11/29/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APTO CUSIPN/A CIK882361 Webwww.aptose.com Phone858-926-2730Fax905-234-2120Employees31Year FoundedN/APrice Target and Rating Average Stock Price Target$37.67 High Stock Price Target$120.00 Low Stock Price Target$12.00 Potential Upside/Downside+1,589.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($7.9281) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,820,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-230.97% Return on Assets-142.96% Debt Debt-to-Equity RatioN/A Current Ratio1.59 Quick Ratio1.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.03 per share Price / Book2.17Miscellaneous Outstanding Shares7,540,000Free Float6,824,000Market Cap$16.81 million OptionableOptionable Beta1.43 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. William G. Rice Ph.D. (Age 59)Chairman, Pres & CEO Mr. Gregory K. Chow CPA (Age 45)MBA, BA, Sr. VP, CFO & Principal Accounting Officer Mr. Ernest Kitt B.S.M.S, VP of Devel. & Technical OperationsDr. Stephen B. Howell (Age 73)Chief Medical Officer Mr. Peter MurrayDirector of Clinical Devel.Key CompetitorsProtara TherapeuticsNASDAQ:TARAPHAXIAM TherapeuticsNASDAQ:PHXMSenti BiosciencesNASDAQ:SNTIBioCardiaNASDAQ:BCDAEiger BioPharmaceuticalsNASDAQ:EIGRView All CompetitorsInsiders & InstitutionsAnnandale Capital LLCBought 21,334 shares on 11/15/2023Ownership: 0.990%Sigma Planning CorpBought 145,786 shares on 11/6/2023Ownership: 1.934%Bernd R SeizingerBought 17,000 shares on 9/22/2023Total: $53,380.00 ($3.14/share)View All Insider TransactionsView All Institutional Transactions APTO Stock Analysis - Frequently Asked Questions Should I buy or sell Aptose Biosciences stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" APTO shares. View APTO analyst ratings or view top-rated stocks. What is Aptose Biosciences' stock price target for 2024? 6 Wall Street research analysts have issued 12 month target prices for Aptose Biosciences' shares. Their APTO share price targets range from $12.00 to $120.00. On average, they predict the company's stock price to reach $37.67 in the next twelve months. This suggests a possible upside of 1,394.7% from the stock's current price. View analysts price targets for APTO or view top-rated stocks among Wall Street analysts. How have APTO shares performed in 2023? Aptose Biosciences' stock was trading at $8.70 at the beginning of 2023. Since then, APTO stock has decreased by 71.0% and is now trading at $2.52. View the best growth stocks for 2023 here. Are investors shorting Aptose Biosciences? Aptose Biosciences saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 30,500 shares, a drop of 27.2% from the October 31st total of 41,900 shares. Based on an average trading volume of 37,400 shares, the days-to-cover ratio is currently 0.8 days. Currently, 1.0% of the company's shares are sold short. View Aptose Biosciences' Short Interest. When is Aptose Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our APTO earnings forecast. How were Aptose Biosciences' earnings last quarter? Aptose Biosciences Inc. (NASDAQ:APTO) posted its quarterly earnings results on Thursday, March, 23rd. The biotechnology company reported ($1.65) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($1.65). During the same quarter in the previous year, the business earned ($4.05) EPS. When did Aptose Biosciences' stock split? Aptose Biosciences's stock reverse split before market open on Tuesday, June 6th 2023. The 1-15 reverse split was announced on Tuesday, June 6th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What is William G. Rice, Ph.D.'s approval rating as Aptose Biosciences' CEO? 8 employees have rated Aptose Biosciences Chief Executive Officer William G. Rice, Ph.D. on Glassdoor.com. William G. Rice, Ph.D. has an approval rating of 34% among the company's employees. This puts William G. Rice, Ph.D. in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 52.0% of employees surveyed would recommend working at Aptose Biosciences to a friend. What other stocks do shareholders of Aptose Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), Cisco Systems (CSCO), Micron Technology (MU) and SCYNEXIS (SCYX). Who are Aptose Biosciences' major shareholders? Aptose Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Sigma Planning Corp (1.93%), Annandale Capital LLC (0.99%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bernd R Seizinger, Denis R Burger, Donald R Jr Wilson, Erich Platzer, Rafael Bejar, Warren Whitehead and William G Rice. View institutional ownership trends. How do I buy shares of Aptose Biosciences? Shares of APTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:APTO) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.